RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to supercharge CAR-T cells against stubborn myeloma
Disease control Recruiting nowThis study tests whether adding dasatinib and quercetin to standard CAR-T therapy can better kill cancer cells in people with multiple myeloma that has returned or not responded to prior treatments. About 44 adults who have tried at least three other therapies will receive the dr…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 06:21 UTC
-
New hope for tough myeloma: drug combo trial launches
Disease control Recruiting nowThis early-phase trial tests a new combination of two drugs—iberdomide and teclistamab—for people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab.…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New dosing strategy aims to tame myeloma Drug's eye side effects
Disease control Recruiting nowThis study tests different doses and schedules of belantamab mafodotin, a targeted therapy for multiple myeloma that has returned or not responded to prior treatments. The goal is to find a dosing plan that reduces serious eye problems while still controlling the cancer. About 62…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Could less be more? new trial aims to cut drug side effects in myeloma
Disease control Recruiting nowThis study tests whether reducing the dose of the drug linvoseltamab after an initial good response can keep multiple myeloma under control while causing fewer side effects. About 30 adults with myeloma that has returned or stopped responding to other treatments will take part. R…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug combo aims to unleash immune system against stubborn myeloma
Disease control Recruiting nowThis early-phase trial tests whether adding a new drug called SX-682 to standard myeloma medications is safe and tolerable for people whose cancer has come back or hasn't responded to prior therapy. SX-682 works by blocking signals that suppress the immune system, potentially hel…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New 4-Drug cocktail aims to beat back relapsed myeloma
Disease control Recruiting nowThis study tests a combination of four drugs (iberdomide, daratumumab, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to shrink or control the canc…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New combo therapy aims to outsmart Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests whether adding a drug called iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for people with multiple myeloma that has come back or stopped responding to prior therapies. About 88 adults will take part. The go…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
CRISPR Gene-Editing trial seeks to supercharge immune cells against incurable blood cancer
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new cell therapy for multiple myeloma that has returned or stopped responding to other treatments. Doctors take a patient's own immune cells, use CRISPR gene-editing technology to reprogram them to hunt down cancer c…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for aggressive myeloma: testing a Triple-Threat drug combo
Disease control Recruiting nowThis study is testing a three-drug combination (MeziKD) for adults with multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. The goal is to see if this combination can shrink these tumors and contro…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Prehabilitation: a simple exercise program may boost strength and quality of life before CAR-T therapy
Symptom relief Recruiting nowThis study looks at whether a personalized exercise program (aerobic and resistance training) done in the weeks before CAR-T therapy can improve physical fitness and quality of life in people aged 60 and older with multiple myeloma that has returned or not responded to treatment.…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 17, 2026 06:16 UTC